[go: up one dir, main page]

CA2370690A1 - Lipides peg cationiques et methodes d'utilisation - Google Patents

Lipides peg cationiques et methodes d'utilisation Download PDF

Info

Publication number
CA2370690A1
CA2370690A1 CA002370690A CA2370690A CA2370690A1 CA 2370690 A1 CA2370690 A1 CA 2370690A1 CA 002370690 A CA002370690 A CA 002370690A CA 2370690 A CA2370690 A CA 2370690A CA 2370690 A1 CA2370690 A1 CA 2370690A1
Authority
CA
Canada
Prior art keywords
lipid
cpl
peg
splp
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370690A
Other languages
English (en)
Inventor
Pieter R. Cullis
Tao Chen
David B. Fenske
Lorne R. Palmer
Kim Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370690A1 publication Critical patent/CA2370690A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention a trait à des conjugats polymère-lipide-cationique (CPL) tel que des conjugats poly(éthylène glycol)-lipide-cationique distaux pouvant être incorporés à des liposomes classiques ou à des liposomes furtifs ou à toute autre formulation à base de lipide pour renforcer l'absorption cellulaire. Les CPL selon l'invention comportent une fraction lipidique, un polymère hydrophile et une fraction polycationique. L'invention concerne également une méthode permettant de renforcer la libération intracellulaire d'acides nucléiques.
CA002370690A 1999-04-20 2000-04-20 Lipides peg cationiques et methodes d'utilisation Abandoned CA2370690A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13015199P 1999-04-20 1999-04-20
US60/130,151 1999-04-20
PCT/CA2000/000451 WO2000062813A2 (fr) 1999-04-20 2000-04-20 Lipides peg cationiques et méthodes d'utilisation

Publications (1)

Publication Number Publication Date
CA2370690A1 true CA2370690A1 (fr) 2000-10-26

Family

ID=22443303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370690A Abandoned CA2370690A1 (fr) 1999-04-20 2000-04-20 Lipides peg cationiques et methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1173600A2 (fr)
JP (2) JP5117648B2 (fr)
AU (1) AU783647B2 (fr)
CA (1) CA2370690A1 (fr)
WO (1) WO2000062813A2 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
JP2004508012A (ja) * 2000-04-20 2004-03-18 ザ　ユニバーシティ　オブ　ブリティッシュ　コロンビア エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
AU2002214854A1 (en) * 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
WO2004082626A2 (fr) * 2003-03-18 2004-09-30 Ethicon, Inc. Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
SG190613A1 (en) 2003-07-16 2013-06-28 Protiva Biotherapeutics Inc Lipid encapsulated interfering rna
EP1664316B1 (fr) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Composes lipidiques modifies avec du polyethyleneglycol et utilisations de ces composes
FR2870741B1 (fr) * 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US8765181B2 (en) * 2005-09-09 2014-07-01 Beijing Diacrid Medical Technology Co., Ltd Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2710713C (fr) 2007-12-27 2017-09-19 Protiva Biotherapeutics, Inc. Silencage de l'expression de la polo-like kinase a l'aide d'un arn interferent
CA2721380A1 (fr) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Reduction au silence de l'expression du gene csn5 au moyen d'arn interferant
US8058069B2 (en) 2008-04-15 2011-11-15 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
WO2009129227A1 (fr) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation de réponse immunitaire par des énantiomères de lipides cationiques
CN105152939A (zh) 2008-11-10 2015-12-16 阿尔尼拉姆医药品有限公司 用于递送治疗剂的脂质和组合物
EP2449114B9 (fr) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Formulations lipidiques inédites permettant l'administration d'agents thérapeutiques en direction de tumeurs solides
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011011447A1 (fr) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions et méthodes pour rendre silencieuse l’expression du gène du virus ebola
US9222086B2 (en) 2009-09-23 2015-12-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
EP3403647A1 (fr) 2009-12-01 2018-11-21 Translate Bio, Inc. Administration d'arnm pour l'augmentation des protéines et des enzymes dans des maladies génétiques humaines
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
AU2011268146A1 (en) 2010-06-17 2013-01-10 Actogenix Nv Compositions and methods for treating inflammatory conditions
WO2012000104A1 (fr) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Systèmes non liposomaux pour une administration d'acide nucléique
US20140206753A1 (en) 2011-06-08 2014-07-24 Shire Human Genetic Therapies, Inc. Lipid nanoparticle compositions and methods for mrna delivery
US11073451B2 (en) 2011-12-19 2021-07-27 Kode Biotech Limited Biocompatible method of functionalising substrates with inert surfaces
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
WO2013126803A1 (fr) 2012-02-24 2013-08-29 Protiva Biotherapeutics Inc. Lipides cationiques trialkylés et leurs procédés d'utilisation
HK1198924A1 (en) * 2012-03-16 2015-06-19 默克专利股份有限公司 Targeting aminoacid lipids
EP2859102A4 (fr) 2012-06-08 2016-05-11 Shire Human Genetic Therapies Polynucléotides résistant à la nucléase et leurs utilisations
CN105163753B (zh) 2012-06-15 2018-12-21 Pds生物科技公司 阳离子脂质疫苗组合物和使用方法
EP2897639A4 (fr) 2012-09-21 2016-05-04 Frank Bedu-Addo Compositions de vaccins perfectionnées et méthodes d'utilisation
CA2904151C (fr) 2013-03-14 2023-09-12 Shire Human Genetic Therapies, Inc. Composition a base d'arnm du gene cftr et procedes et utilisations associes
ES2981185T3 (es) 2013-03-14 2024-10-07 Translate Bio Inc Métodos para la purificación de ARN mensajero
JP6620093B2 (ja) 2013-07-23 2019-12-11 アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ メッセンジャーｒｎａを送達するための組成物及び方法
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
WO2015061491A1 (fr) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Thérapie à l'arnm pour la phénylcétonurie
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
KR20170075742A (ko) 2014-10-02 2017-07-03 프로티바 바이오쎄라퓨틱스, 인코포레이티드 B형 간염 바이러스 유전자 발현을 제거하는 조성물 및 방법
WO2016197132A1 (fr) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Traitement d'une infection à virus de l'hépatite b à de l'aide de crispr
WO2017019891A2 (fr) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
WO2017035278A1 (fr) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Nanoparticules polynucléotidiques pour la modulation de l'expression génique et leurs utilisations
CA3005251A1 (fr) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipides en tant que vecteurs synthetiques pour ameliorer le traitement et la presentation de l'antigene ex-vivo en therapie cellulaire dendritique
EP3478838A1 (fr) 2016-06-30 2019-05-08 Arbutus Biopharma Corporation Compositions et procédés pour l'administration d'arn messager
EP4653462A2 (fr) 2016-08-22 2025-11-26 Arbutus Biopharma Corporation Anticorps anti-pd-1, ou fragments de ceux-ci, pour le traitement de l'hépatite b
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
WO2020041793A1 (fr) 2018-08-24 2020-02-27 Translate Bio, Inc. Procédés de purification d'arn messager
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
GB201910299D0 (en) 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses
CA3162374A1 (fr) * 2019-12-20 2021-06-24 So Jin Lee Kit de preparation de composition de nanoparticules servant a l'administration de medicament, comprenant un sel d'acide polylactique
JP7709981B2 (ja) 2020-03-17 2025-07-17 ジェネヴァント サイエンシズ ゲーエムベーハー 肝星細胞への治療薬の脂質ナノ粒子送達のためのカチオン性脂質
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
EP4466250B1 (fr) 2022-01-31 2025-03-26 Genevant Sciences Gmbh Lipides cationiques ionisables pour nanoparticules lipidiques
AU2023275780A1 (en) 2022-05-25 2024-12-05 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2024214632A1 (fr) * 2023-04-14 2024-10-17 国立大学法人 東京大学 Polymère cationique contenant un groupe phosphonium, et particules polymères et composition pharmaceutique le contenant
WO2025052278A1 (fr) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Lipides cationiques à base de pyrrolidine pour administration de nanoparticules lipidiques d'agents thérapeutiques à des cellules stellaires hépatiques
WO2025158420A1 (fr) 2024-01-25 2025-07-31 Nanocell Therapeutics Holdings B.V. Méthodes et composition pour induire l'activation et l'expression d'adn dans des lymphocytes t
WO2025169168A1 (fr) 2024-02-09 2025-08-14 Nanocell Therapeutics Holdings B.V. Transfection extracorporelle de cellules effectrices immunitaires

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69632401T2 (de) * 1995-06-07 2005-05-19 Imarx Pharmaceutical Corp., Tucson Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung
EP0932390A1 (fr) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Composition de liposomes therapeutiques et procede
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO1998046208A1 (fr) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Systeme de delivrance d'adn de follicule pileux
AU7490098A (en) * 1997-05-15 1998-12-08 Genzyme Corporation Cationic amphiphile formulations
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6110745A (en) * 1997-07-24 2000-08-29 Inex Pharmaceuticals Corp. Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
WO1999065461A2 (fr) * 1998-06-19 1999-12-23 Genzyme Corporation Complexes micellaires d'amphiphiles cationiques
AU2620000A (en) * 1999-01-21 2000-08-07 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
EP1046394A3 (fr) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Nouvelles compositions utilisables pour la délivrance de composés dans une cellule
AU2001236062A1 (en) * 2000-03-02 2001-09-12 Yasuo Ikeda Gpib-lipid bond construct and use thereof

Also Published As

Publication number Publication date
EP1173600A2 (fr) 2002-01-23
AU783647B2 (en) 2005-11-17
WO2000062813A3 (fr) 2001-08-09
JP2002542341A (ja) 2002-12-10
WO2000062813A2 (fr) 2000-10-26
JP2012122075A (ja) 2012-06-28
AU4096200A (en) 2000-11-02
JP5117648B2 (ja) 2013-01-16

Similar Documents

Publication Publication Date Title
AU783647B2 (en) Cationic peg-lipids and methods of use
US6852334B1 (en) Cationic peg-lipids and methods of use
US6320017B1 (en) Polyamide oligomers
EP1328254B1 (fr) Formulations de lipides pour une administration ciblee
EP0783297B1 (fr) Lipides du type ceramide modifies par polyethylene glycol et de liposomes
EP1041976B1 (fr) Oligomeres polyamidiques
US6815432B2 (en) Methods for encapsulating plasmids in lipid bilayers
US6986902B1 (en) Polyanionic polymers which enhance fusogenicity
WO2002087541A1 (fr) Formulations a base de lipides pour transfert genique
WO2005026372A1 (fr) Composes conjugues lipidiques polyethyleneglycol-dialkyloxypropyle et utilisations de ces composes
Nicolazzi et al. Cationic lipids for transfection
WO2006007712A1 (fr) Methodes permettant de distribuer des agents therapeutiques comprenant des conjugues de lipide-polyethylene glycol
KR100723852B1 (ko) 핵산 및 약물 전달용 중성-양이온성 지질
JP2004508012A (ja) エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
Koynova et al. Recent patents in cationic lipid carriers for delivery of nucleic acids
EP1100834B1 (fr) polymères polyanioniques à fusogénicité améliorée
Martin et al. Advances in cationic lipid-mediated gene delivery
AU8006400B2 (fr)
AU2773902A (en) Polyamide oligomers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead